{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Preston MA"],"funding":["NHLBI NIH HHS","NCI NIH HHS"],"pagination":["2705-11"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5019757"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["34(23)"],"pubmed_abstract":["<h4>Purpose</h4>Prostate-specific antigen (PSA) level in midlife predicted future prostate cancer (PCa) mortality in an unscreened Swedish population. Our purpose was to determine if a baseline PSA level during midlife predicts lethal PCa in a US population with opportunistic screening.<h4>Materials and methods</h4>We conducted a nested case-control study among men age 40 to 59 years who gave blood before random assignment in the Physicians' Health Study, a randomized, placebo-controlled trial of aspirin and β-carotene among 22,071 US male physicians initiated in 1982 and then transitioned into a prospective cohort with 30 years of follow-up. Baseline PSA levels were available for 234 patients with PCa and 711 age-matched controls. Seventy-one participants who developed lethal PCa were rem"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer."],"pmcid":["PMC5019757"],"funding_grant_id":["P50 CA092629","R01 HL034595","P30 CA008748","R01 CA097193","R01 CA040360","R01 CA034944","R01 HL026490","R33 CA127768","P50 CA090381"],"pubmed_authors":["Wilson KM","Preston MA","Feldman AS","Sesso HD","Kibel AS","Sjoberg DD","Gerke T","Dahl DM","Mucci LA","Carlsson SV","Batista JL","Gann PH","Vickers AJ"],"additional_accession":[]},"is_claimable":false,"name":"Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.","description":"<h4>Purpose</h4>Prostate-specific antigen (PSA) level in midlife predicted future prostate cancer (PCa) mortality in an unscreened Swedish population. Our purpose was to determine if a baseline PSA level during midlife predicts lethal PCa in a US population with opportunistic screening.<h4>Materials and methods</h4>We conducted a nested case-control study among men age 40 to 59 years who gave blood before random assignment in the Physicians' Health Study, a randomized, placebo-controlled trial of aspirin and β-carotene among 22,071 US male physicians initiated in 1982 and then transitioned into a prospective cohort with 30 years of follow-up. Baseline PSA levels were available for 234 patients with PCa and 711 age-matched controls. Seventy-one participants who developed lethal PCa were rem","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Aug","modification":"2026-05-29T20:33:38.341Z","creation":"2019-03-27T02:24:00Z"},"accession":"S-EPMC5019757","cross_references":{"pubmed":["27298404"],"doi":["10.1200/jco.2016.66.7527","10.1200/JCO.2016.66.7527"]}}